keyword
MENU ▼
Read by QxMD icon Read
search

Aspirin colorectal cancer

keyword
https://www.readbyqxmd.com/read/27920693/capecitabine-induced-coronary-vasospasm
#1
Danish Henry, Francine Rudzik, Allison Butts, Aju Mathew
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is approved for early-stage and advanced colorectal cancer and metastatic breast cancer. Cardiotoxicity of 5-FU is well described in the literature. However, cardiac adverse effects of capecitabine are poorly described. We report a case of coronary vasospasm induced by capecitabine. A 41-year-old female with metastatic breast cancer presented with chest pain 3 days after starting capecitabine. The chest pain was relieved by rest and exacerbated by exertion...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27919915/chemoprevention-of-colorectal-cancer-in-individuals-with-previous-colorectal-neoplasia-systematic-review-and-network-meta-analysis
#2
Parambir S Dulai, Siddharth Singh, Evelyn Marquez, Rohan Khera, Larry J Prokop, Paul J Limburg, Samir Gupta, Mohammad Hassan Murad
OBJECTIVE:  To assess the comparative efficacy and safety of candidate agents (low and high dose aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), calcium, vitamin D, folic acid, alone or in combination) for prevention of advanced metachronous neoplasia (that is, occurring at different times after resection of initial neoplasia) in individuals with previous colorectal neoplasia, through a systematic review and network meta-analysis. DATA SOURCES:  Medline, Embase, Web of Science, from inception to 15 October 2015; clinical trial registries...
December 5, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27859470/non-alcoholic-fatty-liver-diseases-and-risk-of-colorectal-neoplasia
#3
J S Ahn, D H Sinn, Y W Min, S N Hong, H S Kim, S-H Jung, S Gu, P-L Rhee, S W Paik, H J Son, G-Y Gwak
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis. AIM: To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD. METHODS: A total of 26 540 asymptomatic adults who underwent same day first-time colonoscopy and abdominal ultrasonography as a health check-up programme were analysed...
November 18, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27859394/systematic-review-with-meta-analysis-the-comparative-effectiveness-of-aspirin-vs-screening-for-colorectal-cancer-prevention
#4
REVIEW
L Emilsson, Ø Holme, M Bretthauer, N R Cook, J E Buring, M Løberg, H-O Adami, H D Sesso, M J Gaziano, M Kalager
BACKGROUND: Both aspirin use and screening with flexible sigmoidoscopy or guaiac faecal occult blood testing (FOBT) may reduce mortality from colorectal cancer, but comparative effectiveness of these interventions is unknown. AIM: To compare aspirin to guaiac FOBT screening with regard to incidence and mortality of colorectal cancer in a network meta-analysis. METHODS: We searched Medline, EMBASE and the COCHRANE central register (CENTRAL) for relevant randomised trials identified until 31 October 2015...
November 17, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27845951/does-low-dose-aspirin-use-for-cardiovascular-disease-prevention-reduce-colorectal-cancer-deaths-a-comparison-of-two-cohorts-in-the-florence-district-italy
#5
Leonardo Ventura, Guido Miccinesi, Alessandro Barchielli, Gianfranco Manneschi, Donella Puliti, Paola Mantellini, Francesco Orso, Marco Zappa
Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers. The aim of our paper was to study the effect of low-dose aspirin intake on cancer mortality in a population-based cohort study. The study included inhabitants of the Florence district (Italy) at the beginning of 2007. We considered two cohorts: patients who received prescriptions of low-dose aspirin for the whole year and patients who did not have any prescriptions over the same period. We followed the two cohorts until 31 December 2013...
November 14, 2016: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/27837443/do-cancer-survivors-develop-healthier-lifestyle-behaviors-than-the-cancer-free-population-in-the-plco-study
#6
Makenzie L Hawkins, Saundra S Buys, Lisa H Gren, Sara E Simonsen, Anne C Kirchhoff, Mia Hashibe
BACKGROUND: Current studies report mixed results in health status and health behaviors after a diagnosis of cancer. The aim of our study is to investigate potential differences in lifestyle factors among cancer survivors and cancer-free individuals in a prospective cohort study conducted in the United States. METHODS: Using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial, 10,133 cancer survivors were identified and compared to 81,992 participants without cancer to evaluate differences in body mass index (BMI), smoking, NSAID use, and physical activity...
November 11, 2016: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/27835884/combination-of-cox-2-expression-and-pik3ca-mutation-as-prognostic-and-predictive-markers-for-celecoxib-treatment-in-breast-cancer
#7
Sandrine Tury, Véronique Becette, Franck Assayag, Sophie Vacher, Camille Benoist, Maud Kamal, Elisabetta Marangoni, Ivan Bièche, Florence Lerebours, Céline Callens
COX-2 expression level and prognostic value are still a matter of debate in breast cancer (BC). We addressed these points in the context of PIK3CA mutational status. Based on an interesting study of aspirin efficacy in colorectal cancer, we hypothesized that celecoxib antitumoral activity may be restricted to PIK3CA mutated BC.COX-2 mRNA expression was analyzed in 446 BC samples and in 61 BC patient-derived xenografts (PDX) using quantitative RT-PCR. The prognostic impact of COX-2 expression level was assessed independently and according to PIK3CA mutational status in our cohort and in a validation set of 817 BC...
November 8, 2016: Oncotarget
https://www.readbyqxmd.com/read/27789660/does-aspirin-use-reduce-the-risk-for-cancer
#8
Usman Iqbal, Hsuan-Chia Yang, Wen-Shan Jian, Yun Yen, Yu-Chuan Jack Li
Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0...
October 27, 2016: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/27777129/add-aspirin-a-phase-iii-double-blind-placebo-controlled-randomised-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours
#9
Christopher Coyle, Fay H Cafferty, Samuel Rowley, Mairead MacKenzie, Lindy Berkman, Sudeep Gupta, C S Pramesh, Duncan Gilbert, Howard Kynaston, David Cameron, Richard H Wilson, Alistair Ring, Ruth E Langley
BACKGROUND: There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer therapy. METHODS: Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts. Patients who have undergone potentially curative treatment for breast (n=3100), colorectal (n=2600), gastro-oesophageal (n=2100) or prostate cancer (n=2120) are registered into four tumour specific cohorts...
November 2016: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27765797/exploring-differences-in-the-aspirin-colorectal-cancer-association-by-sex-and-race-ethnicity-the-multiethnic-cohort-study
#10
Song-Yi Park, Lynne R Wilkens, Laurence N Kolonel, Kristine R Monroe, Christopher A Haiman, Loic Le Marchand
BACKGROUND: Evidence has accumulated that long-term use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) protects against colorectal cancer (CRC). We tested whether the inverse associations between NSAIDs and CRC is similarly observed across sexes and five racial/ethnic groups (Japanese, Latino, African American, Native Hawaiian, and white) in the Multiethnic Cohort (MEC) Study. METHODS: During a mean follow-up of 16.1 years, we identified 4,882 invasive incident CRC cases among 183,199 eligible participants...
October 10, 2016: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/27724912/risk-factors-for-cancer-development-in-type-2-diabetes-a-retrospective-case-control-study
#11
Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
BACKGROUND: The risk of several types of cancer is increased in type 2 diabetes mellitus. The earliest possible diagnosis of cancer - difficult within regular outpatient diabetes care - is of utmost importance for patients' survival. The aim of this multicenter, retrospective (years 1998-2015), case-control study was to identify risk factors associated with malignancy in subjects with diabetes treated in a typical outpatient setting. METHODS: In the databases of 3 diabetic and 1 primary care clinics 203 patients (115 women) with type 2 diabetes mellitus who developed malignancy while treated for diabetes were identified...
October 10, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27677266/exploring-clinicians-attitudes-about-using-aspirin-for-risk-reduction-in-people-with-lynch-syndrome-with-no-personal-diagnosis-of-colorectal-cancer
#12
Yanni Chen, Michelle Peate, Rajneesh Kaur, Bettina Meiser, Tim Wong, Judy Kirk, Robyn L Ward, Annabel Goodwin, Finlay Macrae, Janet Hiller, Alison H Trainer, Gillian Mitchell
Recent research has shown that aspirin reduces the risk of cancers associated with Lynch Syndrome. However, uncertainty exists around the optimal dosage, treatment duration and whether the benefits of aspirin as a risk-reducing medication (RRM) outweigh adverse medication related side-effects. Little is known about clinicians' attitudes, current practice, and perceived barriers to recommending aspirin as a RRM. To explore the attitudes of clinicians who discuss risk management options with patients with Lynch Syndrome towards using aspirin as a RRM...
September 27, 2016: Familial Cancer
https://www.readbyqxmd.com/read/27672332/prostate-cancer-patients-may-have-an-increased-risk-of-coexisting-advanced-colorectal-neoplasms
#13
Sun-Hye Ko, Myong Ki Baeg, Woong Jin Bae, Pumsoo Kim, Myung-Gyu Choi
BACKGROUND/AIMS: Patients being treated for prostate cancer (PCa) have an increased risk of developing colorectal cancer. However, whether PCa patients are inherently at a higher risk of colorectal neoplasms (CRNs) is unknown. We aimed to investigate the risk of CRNs in PCa patients. MATERIALS AND METHODS: Patients who had been diagnosed with PCa at a tertiary medical center and had colonoscopy within 1 year of the PCa diagnosis were investigated. Patients were propensity-matched 1:2 by age and body mass index to asymptomatic control subjects who had undergone colonoscopy for routine health screening...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27633788/aspirin-inhibits-the-production-of-proangiogenic-15-s-hete-by-platelet-cyclooxygenase-1
#14
Francesca Rauzi, Nicholas S Kirkby, Matthew L Edin, James Whiteford, Darryl C Zeldin, Jane A Mitchell, Timothy D Warner
Regular consumption of low-dose aspirin reduces the occurrence of colorectal, esophageal, stomach, and gastrointestinal cancers. The underlying mechanism is unknown but may be linked to inhibition of angiogenesis. Because the effective doses of aspirin are consistent with the inhibition of cyclooxygenase-1 in platelets, we used liquid chromatography with tandem mass spectrometry analyses and immunoassays of human platelet releasates coupled with angiogenesis assays to search for the mediators of these effects...
December 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27576095/the-role-of-aspirin-as-antitumoral-agent-for-heavily-pretreated-patients-with-metastatic-colorectal-cancer-receiving-capecitabine-monotherapy
#15
Riccardo Giampieri, Angelo Restivo, Valeria Pusceddu, Michela Del Prete, Elena Maccaroni, Alessandro Bittoni, Luca Faloppi, Kalliopi Andrikou, Maristella Bianconi, Francesco Cabras, Rossana Berardi, Luigi Zorcolo, Francesco Scintu, Stefano Cascinu, Mario Scartozzi
BACKGROUND: The potential clinical impact of aspirin use beyond its canonical indications is a novel matter of scientific debate. In patients with metastatic colorectal cancer failing all available options, regorafenib and TAS 102 represent the only chance of treatment. Although effective, these therapeutic options bring along a not-negligible burden in terms of economic costs and toxicity. In this setting, the indication to use aspirin in combination with chemotherapy would potentially represent a medical revolution under the economic and toxicity profile...
August 4, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27561771/aspirin-and-cancer
#16
REVIEW
Paola Patrignani, Carlo Patrono
The place of aspirin in primary prevention remains controversial, with North American and European organizations issuing contradictory treatment guidelines. More recently, the U.S. Preventive Services Task Force recommended "initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years...
August 30, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27543497/the-role-of-aspirin-in-preventing-colorectal-cancer
#17
REVIEW
John Burn, Harsh Sheth
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers in the developed world and is the second leading cause of cancer-related mortality in the UK and USA. Regular use of aspirin can reduce cancer incidence, recurrence, metastasis and cancer-related mortality. SOURCES OF DATA: Peer-reviewed journals, governmental and professional society publications. AREAS OF AGREEMENT: There is a wide body of evidence from observational studies and randomized trials that aspirin reduces risk of CRC...
September 2016: British Medical Bulletin
https://www.readbyqxmd.com/read/27538177/review-aspirin-reduces-colorectal-cancer-incidence-and-mortality-in-patients-at-average-risk
#18
Robert H Fletcher
No abstract text is available yet for this article.
August 16, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27504605/inflammatory-biomarkers-aspirin-and-risk-of-colorectal-cancer-findings-from-the-physicians-health-study
#19
Chul Kim, Xuehong Zhang, Andrew T Chan, Howard D Sesso, Nader Rifai, Meir J Stampfer, Jing Ma
BACKGROUND: Chronic inflammation has been implicated in colorectal carcinogenesis. However, the associations between plasma inflammatory markers and risk of colorectal cancer have been inconsistent. METHODS: In a nested case-control study in the Physicians' Health Study, we prospectively investigated the associations of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 2 (TNFR-2) with risk of colorectal cancer, and whether aspirin modified these associations among 268 colorectal cancer patients and 446 age- and smoking-matched controls...
October 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27490113/modeling-the-prevention-of-colorectal-cancer-from-the-combined-impact-of-host-and-behavioral-risk-factors
#20
Matthew Frampton, Richard S Houlston
PURPOSE: This study investigated the utility of modeling modifiable lifestyle risk factors in addition to genetic variation in colorectal cancer (CRC) screening/prevention. METHODS: We derived a polygenic risk score for CRC susceptibility variants in combination with the established nongenetic risk factors of inflammatory bowel disease (IBD), adiposity, alcohol, red meat, fruit, vegetables, smoking, physical activity, and aspirin. We used the 37 known risk variants and 50 and 100% of all risk variants as calculated from a heritability estimate...
August 4, 2016: Genetics in Medicine: Official Journal of the American College of Medical Genetics
keyword
keyword
30001
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"